A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Characteristics of Single Dose Subcutaneous Administration of AK115 in Healthy Subjects
Latest Information Update: 04 Mar 2025
At a glance
- Drugs AK-115 (Primary)
- Indications Cancer pain; Pain
- Focus Adverse reactions
- Sponsors Akeso Biopharma
Most Recent Events
- 28 Feb 2025 Status changed from not yet recruiting to completed.
- 10 Mar 2022 Status changed from planning to not yet recruiting.
- 15 Feb 2022 New trial record